Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. COLUMBUS was a two-part, randomised, open-label,...
Saved in:
Published in | The lancet oncology Vol. 19; no. 10; pp. 1315 - 1327 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.10.2018
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival.
COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAFV600E or BRAFV600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38.
Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9–37·5). Median overall survival was 33·6 months (95% CI 24·4–39·2) with encorafenib plus binimetinib and 16·9 months (14·0–24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47–0·79]; two-sided p<0·0001). The most common grade 3 or 4 adverse events did not change substantially from the first report; those seen in more than 5% of patients treated with encorafenib plus binimetinib were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased blood creatine phosphokinase (14 [7%]), and hypertension (12 [6%]); those seen with encorafenib alone were palmar-plantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and with vemurafenib the most common grade 3 or 4 adverse event was arthralgia (11 [6%] of 186 patients). One death in the combination treatment group was considered by the investigator to be possibly related to treatment.
The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma.
Array BioPharma, Novartis. |
---|---|
AbstractList | Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival.
COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAFV600E or BRAFV600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38.
Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9–37·5). Median overall survival was 33·6 months (95% CI 24·4–39·2) with encorafenib plus binimetinib and 16·9 months (14·0–24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47–0·79]; two-sided p<0·0001). The most common grade 3 or 4 adverse events did not change substantially from the first report; those seen in more than 5% of patients treated with encorafenib plus binimetinib were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased blood creatine phosphokinase (14 [7%]), and hypertension (12 [6%]); those seen with encorafenib alone were palmar-plantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and with vemurafenib the most common grade 3 or 4 adverse event was arthralgia (11 [6%] of 186 patients). One death in the combination treatment group was considered by the investigator to be possibly related to treatment.
The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma.
Array BioPharma, Novartis. Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAF or BRAF mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38. Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9-37·5). Median overall survival was 33·6 months (95% CI 24·4-39·2) with encorafenib plus binimetinib and 16·9 months (14·0-24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47-0·79]; two-sided p<0·0001). The most common grade 3 or 4 adverse events did not change substantially from the first report; those seen in more than 5% of patients treated with encorafenib plus binimetinib were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased blood creatine phosphokinase (14 [7%]), and hypertension (12 [6%]); those seen with encorafenib alone were palmar-plantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and with vemurafenib the most common grade 3 or 4 adverse event was arthralgia (11 [6%] of 186 patients). One death in the combination treatment group was considered by the investigator to be possibly related to treatment. The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAF -mutant melanoma. Array BioPharma, Novartis. BACKGROUNDEncorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival.METHODSCOLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAFV600E or BRAFV600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38.FINDINGSBetween Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9-37·5). Median overall survival was 33·6 months (95% CI 24·4-39·2) with encorafenib plus binimetinib and 16·9 months (14·0-24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47-0·79]; two-sided p<0·0001). The most common grade 3 or 4 adverse events did not change substantially from the first report; those seen in more than 5% of patients treated with encorafenib plus binimetinib were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased blood creatine phosphokinase (14 [7%]), and hypertension (12 [6%]); those seen with encorafenib alone were palmar-plantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and with vemurafenib the most common grade 3 or 4 adverse event was arthralgia (11 [6%] of 186 patients). One death in the combination treatment group was considered by the investigator to be possibly related to treatment.INTERPRETATIONThe combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma.FUNDINGArray BioPharma, Novartis. Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. Methods COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAFV600E or BRAFV600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had progressed on or after first-line immunotherapy. In part 1 of the study, patients were randomly assigned (1:1:1) by use of interactive response technology to receive oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group). Randomisation was stratified by the American Joint Committee on Cancer stage, ECOG performance status, and BRAF mutation status. The primary outcome of the trial, progression-free survival with encorafenib plus binimetinib versus vemurafenib, was reported previously. Here we present the prespecified interim overall survival analysis. Efficacy analyses were by intent to treat. Safety was analysed in patients who received at least one dose of study drug. Part 2 of the study was initiated at the request of the US Food and Drug Administration to better understand the contribution of binimetinib to the combination therapy by comparing encorafenib 300 mg once daily plus binimetinib 45 mg twice daily with encorafenib 300 mg once daily alone. Results of part 2 will be published separately. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01909453, and EudraCT, number 2013-001176-38. Findings Between Dec 30, 2013, and April 10, 2015, 577 of 1345 screened patients were randomly assigned to receive encorafenib plus binimetinib (n=192), encorafenib (n=194), or vemurafenib (n=191). Median follow-up for overall survival was 36·8 months (95% CI 35·9–37·5). Median overall survival was 33·6 months (95% CI 24·4–39·2) with encorafenib plus binimetinib and 16·9 months (14·0–24·5) with vemurafenib (hazard ratio 0·61 [95% CI 0·47–0·79]; two-sided p<0·0001). The most common grade 3 or 4 adverse events did not change substantially from the first report; those seen in more than 5% of patients treated with encorafenib plus binimetinib were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased blood creatine phosphokinase (14 [7%]), and hypertension (12 [6%]); those seen with encorafenib alone were palmar-plantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and with vemurafenib the most common grade 3 or 4 adverse event was arthralgia (11 [6%] of 186 patients). One death in the combination treatment group was considered by the investigator to be possibly related to treatment. Interpretation The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma. Funding Array BioPharma, Novartis. |
Author | Gutzmer, Ralf Robert, Caroline Mandala, Mario Liszkay, Gabriella Krajsova, Ivana Gogas, Helen J Dutriaux, Caroline Dummer, Reinhard Moutouh-de Parseval, Laure A Arance, Ana Flaherty, Keith T Chiarion Sileni, Vanna Yamazaki, Naoya Pickard, Michael D de Groot, Jan Willem B Garbe, Claus Schadendorf, Dirk Loquai, Carmen Ascierto, Paolo A Sandor, Victor |
Author_xml | – sequence: 1 givenname: Reinhard surname: Dummer fullname: Dummer, Reinhard email: reinhard.dummer@usz.ch organization: Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland – sequence: 2 givenname: Paolo A surname: Ascierto fullname: Ascierto, Paolo A organization: Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy – sequence: 3 givenname: Helen J surname: Gogas fullname: Gogas, Helen J organization: Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece – sequence: 4 givenname: Ana surname: Arance fullname: Arance, Ana organization: Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain – sequence: 5 givenname: Mario surname: Mandala fullname: Mandala, Mario organization: Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy – sequence: 6 givenname: Gabriella surname: Liszkay fullname: Liszkay, Gabriella organization: Department of Dermatology, National Institute of Oncology, Budapest, Hungary – sequence: 7 givenname: Claus surname: Garbe fullname: Garbe, Claus organization: Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany – sequence: 8 givenname: Dirk surname: Schadendorf fullname: Schadendorf, Dirk organization: Department of Dermatology, University Hospital Essen, Essen, Germany – sequence: 9 givenname: Ivana surname: Krajsova fullname: Krajsova, Ivana organization: Department of Dermato-oncology, University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic – sequence: 10 givenname: Ralf surname: Gutzmer fullname: Gutzmer, Ralf organization: Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany – sequence: 11 givenname: Vanna surname: Chiarion Sileni fullname: Chiarion Sileni, Vanna organization: Melanoma Cancer Unit, Oncology Institute of Veneto IRCCS, Padua, Italy – sequence: 12 givenname: Caroline surname: Dutriaux fullname: Dutriaux, Caroline organization: Department of Oncologic Dermatology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux Cédex, France – sequence: 13 givenname: Jan Willem B surname: de Groot fullname: de Groot, Jan Willem B organization: Department of Medical Oncology, Isala, Zwolle, Netherlands – sequence: 14 givenname: Naoya surname: Yamazaki fullname: Yamazaki, Naoya organization: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan – sequence: 15 givenname: Carmen surname: Loquai fullname: Loquai, Carmen organization: Department of Dermatology, University Medical Center Mainz, Mainz, Germany – sequence: 16 givenname: Laure A surname: Moutouh-de Parseval fullname: Moutouh-de Parseval, Laure A organization: Translational Clinical Oncology, Novartis Pharma AG, Basel, Switzerland – sequence: 17 givenname: Michael D surname: Pickard fullname: Pickard, Michael D organization: Array BioPharma, Boulder, CO, USA – sequence: 18 givenname: Victor surname: Sandor fullname: Sandor, Victor organization: Array BioPharma, Boulder, CO, USA – sequence: 19 givenname: Caroline surname: Robert fullname: Robert, Caroline organization: Service of Dermatology, Department of Medicine and Paris-Sud University, Gustave Roussy, Villejuif Cedex, France – sequence: 20 givenname: Keith T surname: Flaherty fullname: Flaherty, Keith T organization: Cancer Center, Massachusetts General Hospital, Boston, MA, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30219628$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkV1rFDEUhoNUbLv6E5SAN1vY0WQmmQ9vpF2sCisL1r0OmcwZm5JJpklmxH_nTzO72wp641XC4TkfvM85OrHOAkIvKXlDCS3f3lBWkSwnjC9pfVEQ1lRZ_gSdpTLLOKvrk8P_iJyi8xDuCKEVJfwZOi1ITpsyr8_Qr-0MXhqDw-RnPUuDtcWjjBpsDPiHjrf46uvldTZMUdqIBzDSukFiDwr0rO13DFY5L3uwusWjmQJutdUDRL0vpOEhlWYYpkfG-b9aluvtZvflandz8Q5LPEwmapV2e1hhN4LNjGzBrLCXtnODDtCt8HgrA-ACR6-leY6e9tIEePHwLtDu-sO39adss_34eX25yRRjPGY9b9uySTH1JWs47aQEDmWR5zWTJbCiYG1XAeWqK4G3rO0LTsu6KlTTl4p0vFig5XHu6N39BCGKdI0Ck_IANwWRU1LnnHJGE_r6H_TOTd6m6xJFeU7KOp2yQPxIKe9C8NCL0etB-p-CErFXLA6Kxd6foLU4KBZ56nv1MH1qB-j-dD06TcD7IwApjlmDF0ElnQo6naxF0Tn9nxW_AUM6ud4 |
CitedBy_id | crossref_primary_10_1016_S0140_6736_21_01206_X crossref_primary_10_1158_0008_5472_CAN_20_1496 crossref_primary_10_1158_2767_9764_CRC_22_0486 crossref_primary_10_1038_s41467_020_15546_9 crossref_primary_10_1016_j_det_2022_07_007 crossref_primary_10_1007_s12328_022_01599_4 crossref_primary_10_3390_ijms22073474 crossref_primary_10_1055_a_1700_9298 crossref_primary_10_3389_fimmu_2019_00990 crossref_primary_10_1016_j_lungcan_2021_05_021 crossref_primary_10_1111_pcmr_12824 crossref_primary_10_1111_cas_15450 crossref_primary_10_3390_ijms21239001 crossref_primary_10_1016_j_lungcan_2023_107313 crossref_primary_10_1158_1078_0432_CCR_21_3872 crossref_primary_10_1136_esmoopen_2019_000491 crossref_primary_10_3390_biomedicines11123264 crossref_primary_10_1016_j_piel_2019_07_012 crossref_primary_10_2147_OTT_S278095 crossref_primary_10_3390_cancers11091342 crossref_primary_10_3390_jcm13061607 crossref_primary_10_1016_j_celrep_2020_107764 crossref_primary_10_1016_j_soc_2020_03_001 crossref_primary_10_1016_j_annder_2021_04_005 crossref_primary_10_1111_ddg_13766 crossref_primary_10_3390_biomedicines9020096 crossref_primary_10_1080_14740338_2020_1817376 crossref_primary_10_3390_jcm11030828 crossref_primary_10_7717_peerj_14126 crossref_primary_10_1002_tre_910 crossref_primary_10_1016_j_critrevonc_2022_103646 crossref_primary_10_1158_0008_5472_CAN_21_4152 crossref_primary_10_1080_17512433_2019_1650641 crossref_primary_10_1007_s00761_019_00648_x crossref_primary_10_1093_jnen_nlaa042 crossref_primary_10_1146_annurev_cancerbio_030419_033533 crossref_primary_10_17925_EOH_2018_14_2_78 crossref_primary_10_1016_j_ejca_2019_11_016 crossref_primary_10_1186_s13045_020_00977_0 crossref_primary_10_1200_JCO_23_01136 crossref_primary_10_1177_1078155220953877 crossref_primary_10_1111_ddg_15164_g crossref_primary_10_1007_s40262_019_00753_5 crossref_primary_10_1111_bjd_20756 crossref_primary_10_1080_0284186X_2023_2165449 crossref_primary_10_1007_s10637_023_01364_5 crossref_primary_10_1080_14737159_2020_1782194 crossref_primary_10_1080_14740338_2022_1986000 crossref_primary_10_1200_JCO_23_01380 crossref_primary_10_1038_s41598_020_61818_1 crossref_primary_10_3390_cancers16020470 crossref_primary_10_1016_j_ctrv_2020_101997 crossref_primary_10_1016_j_ctrv_2020_101998 crossref_primary_10_1016_j_soc_2020_02_009 crossref_primary_10_1021_acs_jmedchem_0c01609 crossref_primary_10_1111_1346_8138_15813 crossref_primary_10_2147_CMAR_S286917 crossref_primary_10_1002_pbc_28200 crossref_primary_10_2147_OTT_S248237 crossref_primary_10_1093_annonc_mdz411 crossref_primary_10_1016_j_canlet_2020_11_036 crossref_primary_10_1093_neuonc_noab247 crossref_primary_10_3390_jcm9082430 crossref_primary_10_1200_JCO_22_01763 crossref_primary_10_3389_fonc_2022_794216 crossref_primary_10_1016_j_annder_2020_11_006 crossref_primary_10_3389_fmed_2019_00140 crossref_primary_10_1097_MD9_0000000000000197 crossref_primary_10_3390_cancers12103004 crossref_primary_10_3390_cancers16081571 crossref_primary_10_1016_j_ctrv_2024_102795 crossref_primary_10_1007_s11864_021_00827_2 crossref_primary_10_1111_cpr_13009 crossref_primary_10_1186_s13046_022_02584_y crossref_primary_10_3390_ijms25031725 crossref_primary_10_1200_EDBK_397478 crossref_primary_10_3389_fmolb_2022_864302 crossref_primary_10_1007_s12325_024_02883_0 crossref_primary_10_1111_ddg_14501 crossref_primary_10_21886_2712_8156_2023_4_3_36_44 crossref_primary_10_1177_1535370220959657 crossref_primary_10_1016_j_hoc_2020_09_005 crossref_primary_10_1016_j_neo_2020_10_009 crossref_primary_10_1038_s43018_020_0067_x crossref_primary_10_1080_17512433_2019_1570847 crossref_primary_10_1016_j_ejca_2023_113392 crossref_primary_10_1002_ijc_34807 crossref_primary_10_23736_S2784_8671_21_06936_4 crossref_primary_10_1515_pteridines_2020_0009 crossref_primary_10_6004_jnccn_2020_7569 crossref_primary_10_1016_j_jid_2020_06_041 crossref_primary_10_3892_or_2024_8726 crossref_primary_10_1080_23808993_2021_1847639 crossref_primary_10_3390_cancers13194780 crossref_primary_10_3389_fonc_2023_1268693 crossref_primary_10_1093_neuonc_noaa263 crossref_primary_10_3389_fmolb_2020_606593 crossref_primary_10_2196_29912 crossref_primary_10_1097_CAD_0000000000000798 crossref_primary_10_1111_dth_14544 crossref_primary_10_1016_j_canlet_2021_12_031 crossref_primary_10_1080_14656566_2020_1729122 crossref_primary_10_1097_CCO_0000000000000606 crossref_primary_10_1186_s12885_019_5864_1 crossref_primary_10_1186_s13045_022_01362_9 crossref_primary_10_3390_cancers12102801 crossref_primary_10_1002_cam4_3474 crossref_primary_10_1097_CMR_0000000000000882 crossref_primary_10_1158_1078_0432_CCR_23_0090 crossref_primary_10_1002_slct_202100906 crossref_primary_10_1007_s11523_020_00727_9 crossref_primary_10_3390_cancers13246312 crossref_primary_10_1080_14740338_2021_1965990 crossref_primary_10_3390_curroncol28050338 crossref_primary_10_3390_cancers12061500 crossref_primary_10_1097_CCO_0000000000000614 crossref_primary_10_1111_bjd_19394 crossref_primary_10_1097_CMR_0000000000000750 crossref_primary_10_1055_a_1933_8141 crossref_primary_10_1200_JCO_20_00198 crossref_primary_10_1001_jamanetworkopen_2019_8890 crossref_primary_10_1158_1078_0432_CCR_21_2138 crossref_primary_10_36290_xon_2023_022 crossref_primary_10_3389_fonc_2020_571135 crossref_primary_10_1097_CMR_0000000000000662 crossref_primary_10_3389_fonc_2021_670726 crossref_primary_10_1007_s15012_019_2964_1 crossref_primary_10_1016_j_semcancer_2019_08_024 crossref_primary_10_3238_arztebl_2019_0497 crossref_primary_10_2169_internalmedicine_8439_21 crossref_primary_10_1016_j_hoc_2020_08_010 crossref_primary_10_1155_2022_8172866 crossref_primary_10_1089_thy_2023_0547 crossref_primary_10_1080_0284186X_2021_1992010 crossref_primary_10_1136_jitc_2022_005828 crossref_primary_10_1016_j_suc_2019_09_013 crossref_primary_10_1097_CMR_0000000000000891 crossref_primary_10_1016_j_ejca_2020_08_012 crossref_primary_10_1097_CCO_0000000000000710 crossref_primary_10_1016_j_coms_2021_11_010 crossref_primary_10_1016_j_lungcan_2022_05_014 crossref_primary_10_1016_j_adengl_2020_07_005 crossref_primary_10_1200_JCO_21_02659 crossref_primary_10_1016_j_xcrm_2023_101002 crossref_primary_10_1111_ddg_14501_g crossref_primary_10_1007_s11307_021_01666_1 crossref_primary_10_1158_1078_0432_CCR_19_1895 crossref_primary_10_1097_CAD_0000000000000827 crossref_primary_10_1056_NEJMoa1908075 crossref_primary_10_1007_s11912_024_01547_0 crossref_primary_10_1097_CMR_0000000000000690 crossref_primary_10_17925_OHR_2020_16_1_31 crossref_primary_10_3390_cancers15235521 crossref_primary_10_3390_cancers11091262 crossref_primary_10_1097_CMR_0000000000000678 crossref_primary_10_1056_NEJMra2034861 crossref_primary_10_1080_17460441_2020_1795124 crossref_primary_10_1097_CCO_0000000000000817 crossref_primary_10_1016_j_esmoop_2023_100788 crossref_primary_10_1111_imj_15228 crossref_primary_10_1016_j_annonc_2021_10_010 crossref_primary_10_1200_JCO_18_02459 crossref_primary_10_3390_cancers15153754 crossref_primary_10_1684_ejd_2019_3511 crossref_primary_10_3389_fonc_2021_771335 crossref_primary_10_1016_j_pharmthera_2022_108301 crossref_primary_10_3390_curroncol28050304 crossref_primary_10_1016_j_omtn_2019_10_005 crossref_primary_10_1111_pcmr_12880 crossref_primary_10_1002_ijc_32696 crossref_primary_10_3390_cancers15010031 crossref_primary_10_1016_j_esmoop_2021_100050 crossref_primary_10_1080_0284186X_2019_1670862 crossref_primary_10_1097_DAD_0000000000001592 crossref_primary_10_1007_s15015_020_3353_7 crossref_primary_10_1007_s00761_020_00762_1 crossref_primary_10_1007_s10637_023_01374_3 crossref_primary_10_1016_S2096_6911_21_00075_3 crossref_primary_10_1002_cam4_3103 crossref_primary_10_1007_s11864_019_0607_8 crossref_primary_10_3389_fimmu_2022_725679 crossref_primary_10_3892_ol_2022_13613 crossref_primary_10_1093_jnci_djaa012 crossref_primary_10_1007_s00280_023_04544_5 crossref_primary_10_1097_CMR_0000000000000696 crossref_primary_10_3390_cancers15153856 crossref_primary_10_3389_fgene_2022_885391 crossref_primary_10_1007_s11523_020_00735_9 crossref_primary_10_3390_cancers15010141 crossref_primary_10_1245_s10434_020_08566_8 crossref_primary_10_3390_ijms21238984 crossref_primary_10_1200_JCO_22_02322 crossref_primary_10_1016_j_ejca_2020_07_016 crossref_primary_10_1111_1346_8138_17147 crossref_primary_10_1080_14737140_2022_2017286 crossref_primary_10_1158_1078_0432_CCR_19_3809 crossref_primary_10_1016_j_semcancer_2019_10_010 crossref_primary_10_1002_ijc_32358 crossref_primary_10_1111_ddg_14293_g crossref_primary_10_3390_jpm11060518 crossref_primary_10_1186_s40425_019_0569_1 crossref_primary_10_3390_cancers13061421 crossref_primary_10_1080_17460441_2021_1942834 crossref_primary_10_1016_j_jid_2024_03_029 crossref_primary_10_1200_JCO_20_02088 crossref_primary_10_3389_fonc_2020_01056 crossref_primary_10_2217_fon_2023_0414 crossref_primary_10_1038_s41467_021_26572_6 crossref_primary_10_1097_RLU_0000000000004988 crossref_primary_10_3390_cancers12071823 crossref_primary_10_1007_s11523_020_00768_0 crossref_primary_10_3390_cancers15184587 crossref_primary_10_3390_ijms21249730 crossref_primary_10_1016_S2667_0623_23_00204_0 crossref_primary_10_1007_s40257_021_00593_9 crossref_primary_10_1080_10799893_2020_1804280 crossref_primary_10_1007_s11912_019_0849_4 crossref_primary_10_1016_j_bulcan_2020_12_014 crossref_primary_10_1111_ddg_14293 crossref_primary_10_2217_mmt_2019_0010 crossref_primary_10_1007_s10585_021_10099_7 crossref_primary_10_1002_slct_202302031 crossref_primary_10_3390_ph13120418 crossref_primary_10_1002_pds_5630 crossref_primary_10_3389_fcell_2021_760705 crossref_primary_10_1016_S1470_2045_20_30758_0 crossref_primary_10_1093_annonc_mdz165 crossref_primary_10_3390_biomedicines10020284 crossref_primary_10_1093_nop_npaa006 crossref_primary_10_1111_cts_13662 crossref_primary_10_3390_ijms24010859 crossref_primary_10_1007_s10143_022_01839_8 crossref_primary_10_1158_2326_6066_CIR_19_0743 crossref_primary_10_1016_j_ejca_2020_02_021 crossref_primary_10_1007_s13691_024_00674_6 crossref_primary_10_1007_s11912_019_0827_x crossref_primary_10_1016_j_bbagen_2020_129736 crossref_primary_10_1214_22_AOAS1696 crossref_primary_10_3389_fphar_2021_712995 crossref_primary_10_1007_s11864_021_00852_1 crossref_primary_10_1007_s11523_020_00767_1 crossref_primary_10_1111_jdv_18871 crossref_primary_10_1016_j_hoc_2024_05_006 crossref_primary_10_3390_cancers12051176 crossref_primary_10_1016_j_annonc_2020_11_005 crossref_primary_10_1016_j_ejca_2019_07_016 crossref_primary_10_1097_CMR_0000000000000843 crossref_primary_10_1016_j_ebiom_2023_104774 crossref_primary_10_1200_JCO_23_00774 crossref_primary_10_1097_CMR_0000000000000604 crossref_primary_10_2217_fon_2021_1250 crossref_primary_10_1080_03009734_2020_1826612 crossref_primary_10_1016_j_ejca_2024_114073 crossref_primary_10_1158_1078_0432_CCR_19_3550 crossref_primary_10_1007_s40267_019_00609_9 crossref_primary_10_3390_jcm12206447 crossref_primary_10_1097_CM9_0000000000002692 crossref_primary_10_3389_fcell_2020_00486 crossref_primary_10_1016_j_ejca_2020_09_031 crossref_primary_10_1093_oncolo_oyab068 crossref_primary_10_3390_healthcare12010105 crossref_primary_10_3390_ph16070935 crossref_primary_10_1371_journal_pone_0252314 crossref_primary_10_1016_j_canlet_2020_01_034 crossref_primary_10_3390_ijms23179520 crossref_primary_10_1007_s00262_021_03088_y crossref_primary_10_1007_s40257_022_00678_z crossref_primary_10_1016_j_ejca_2019_08_032 crossref_primary_10_1136_jitc_2020_000948 crossref_primary_10_1634_theoncologist_2018_0876 crossref_primary_10_3390_cancers15123126 crossref_primary_10_1186_s41231_022_00133_5 crossref_primary_10_3390_cancers12020482 crossref_primary_10_3390_cancers11111642 crossref_primary_10_3390_jcm9020318 crossref_primary_10_52827_hititmedj_1429875 crossref_primary_10_1007_s11864_019_0680_z crossref_primary_10_1021_acs_molpharmaceut_3c00016 crossref_primary_10_1097_CMR_0000000000000740 crossref_primary_10_1200_PO_19_00174 crossref_primary_10_1016_j_ctrv_2020_102060 crossref_primary_10_1200_JCO_22_01066 crossref_primary_10_1111_ddg_15164 crossref_primary_10_1007_s11912_022_01225_z crossref_primary_10_1016_j_mcna_2021_04_005 crossref_primary_10_1016_j_xkme_2020_01_012 crossref_primary_10_3390_cancers14153587 crossref_primary_10_3390_ijms20184484 crossref_primary_10_3390_cancers11081176 crossref_primary_10_1136_bmjopen_2022_063700 crossref_primary_10_1158_1535_7163_MCT_19_0457 crossref_primary_10_2217_fon_2020_0643 crossref_primary_10_3390_biomedicines10102424 crossref_primary_10_1073_pnas_2206824119 crossref_primary_10_1080_14756366_2019_1605364 crossref_primary_10_1177_27325016211013880 crossref_primary_10_1007_s10147_022_02264_z crossref_primary_10_1080_14740338_2019_1607289 crossref_primary_10_1080_23808993_2021_1976637 crossref_primary_10_1016_j_ejca_2019_01_017 crossref_primary_10_1080_13543784_2020_1769066 crossref_primary_10_3390_cancers12020512 crossref_primary_10_1007_s11864_019_0649_y crossref_primary_10_1007_s40257_020_00509_z crossref_primary_10_3892_or_2021_8109 crossref_primary_10_1177_1758835919851663 crossref_primary_10_1111_apt_17352 crossref_primary_10_1186_s12913_023_09058_7 crossref_primary_10_1016_j_trecan_2020_05_009 crossref_primary_10_1200_PO_21_00561 crossref_primary_10_1002_cam4_3938 crossref_primary_10_1080_17460441_2020_1746265 crossref_primary_10_2217_fon_2019_0748 crossref_primary_10_3390_jpm12101746 crossref_primary_10_1038_s41591_020_1060_8 crossref_primary_10_3390_life10090208 crossref_primary_10_1111_his_14210 crossref_primary_10_1080_00498254_2023_2250856 crossref_primary_10_3389_fonc_2021_710585 crossref_primary_10_3390_cancers15051426 crossref_primary_10_1007_s12094_019_02207_7 crossref_primary_10_1200_EDBK_404770 crossref_primary_10_1016_j_ctrv_2022_102463 crossref_primary_10_1177_1203475420988862 crossref_primary_10_1080_14737140_2020_1787156 crossref_primary_10_1016_j_ctrv_2022_102340 crossref_primary_10_1111_bjd_18947 crossref_primary_10_1007_s11912_022_01306_z crossref_primary_10_1016_S0151_9638_18_31288_2 crossref_primary_10_1016_j_coph_2019_05_010 crossref_primary_10_5021_ad_22_200 crossref_primary_10_1158_1535_7163_MCT_22_0302 crossref_primary_10_1111_jdv_15527 crossref_primary_10_1186_s40164_020_00159_1 crossref_primary_10_5227_skincancer_37_67 crossref_primary_10_1016_j_annonc_2020_07_004 crossref_primary_10_1080_14737140_2020_1711737 crossref_primary_10_1097_CCO_0000000000001014 crossref_primary_10_3389_fonc_2022_975642 crossref_primary_10_1016_j_ejps_2022_106311 crossref_primary_10_1038_s41540_019_0113_4 crossref_primary_10_1111_1346_8138_15688 crossref_primary_10_3390_cancers14030777 crossref_primary_10_1016_j_ejmech_2021_114040 crossref_primary_10_1200_EDBK_438654 crossref_primary_10_3390_molecules28145478 crossref_primary_10_3390_cancers12113456 crossref_primary_10_1177_1758835920925219 crossref_primary_10_1080_17476348_2020_1714441 crossref_primary_10_1530_EJE_21_0797 crossref_primary_10_1038_s41573_019_0046_z crossref_primary_10_1111_jdv_16678 crossref_primary_10_1016_j_ccell_2020_03_014 crossref_primary_10_1007_s10198_023_01614_6 crossref_primary_10_5694_mja2_51910 crossref_primary_10_3389_fonc_2019_00263 crossref_primary_10_1111_ddg_13766_g crossref_primary_10_1136_jitc_2021_004095 crossref_primary_10_1080_14737159_2023_2258063 crossref_primary_10_3390_cells9020417 crossref_primary_10_6004_jnccn_2019_0018 crossref_primary_10_1111_pcmr_13059 crossref_primary_10_1016_j_ejca_2021_04_028 crossref_primary_10_5227_skincancer_37_16 crossref_primary_10_1016_j_annonc_2020_12_012 crossref_primary_10_3389_fonc_2022_917999 crossref_primary_10_1002_cam4_7257 crossref_primary_10_1007_s10585_024_10291_5 crossref_primary_10_1056_NEJMoa1904059 crossref_primary_10_3390_ijms25010624 crossref_primary_10_1016_j_ad_2020_07_003 crossref_primary_10_1158_1078_0432_CCR_21_2761 crossref_primary_10_1007_s11912_022_01205_3 crossref_primary_10_1002_slct_202204248 crossref_primary_10_1111_jdv_16894 crossref_primary_10_21518_2079_701X_2021_9_48_63 crossref_primary_10_1371_journal_pcbi_1009919 crossref_primary_10_1016_j_tranon_2019_10_003 crossref_primary_10_1002_cncr_33515 crossref_primary_10_1016_j_bioorg_2020_104145 crossref_primary_10_1038_s41540_021_00211_8 crossref_primary_10_3389_fonc_2024_1191217 crossref_primary_10_1002_cncr_32547 crossref_primary_10_1016_j_ejca_2023_113425 crossref_primary_10_1080_00498254_2023_2246153 crossref_primary_10_1001_jamanetworkopen_2022_45269 crossref_primary_10_1016_j_celrep_2022_110634 crossref_primary_10_3390_cancers14194930 |
Cites_doi | 10.1056/NEJMoa1210093 10.1093/annonc/mdx176 10.1158/1078-0432.CCR-16-2923 10.1016/j.ejca.2008.10.026 10.1038/ng.3361 10.1056/NEJMoa1002011 10.1056/NEJMoa1406037 10.1056/NEJMoa1708539 10.1200/jco.2014.32.15_suppl.9011 10.1200/jco.2011.29.18_suppl.cra8503 10.1038/nature09454 10.1002/sim.4780091207 10.1200/jco.2015.33.15_suppl.9007 10.1016/S0959-8049(16)31820-2 10.1016/S0140-6736(15)60898-4 10.1097/CCO.0000000000000426 10.1016/S1470-2045(18)30142-6 10.1056/NEJMoa1412690 10.1200/JCO.2011.41.1660 10.1056/NEJMc1113752 10.1056/NEJMoa1408868 10.1016/j.ejca.2016.06.018 10.1016/S1470-2045(16)30122-X 10.1093/annonc/mdw435.37 10.1016/S1470-2045(14)70051-8 10.1038/nature00766 10.1371/journal.pone.0058721 |
ContentType | Journal Article |
Copyright | 2018 Elsevier Ltd Copyright © 2018 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Oct 2018 |
Copyright_xml | – notice: 2018 Elsevier Ltd – notice: Copyright © 2018 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Oct 2018 |
DBID | NPM AAYXX CITATION 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1016/S1470-2045(18)30497-2 |
DatabaseName | PubMed CrossRef Pharma and Biotech Premium PRO ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Pharma and Biotech Premium PRO |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1474-5488 |
EndPage | 1327 |
ExternalDocumentID | 10_1016_S1470_2045_18_30497_2 30219628 S1470204518304972 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation | Array BioPharma, Novartis. |
GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 3V. 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABLVK ABMAC ABMZM ABUWG ABYKQ ACGFS ACPRK ACRLP ADBBV ADMUD AEKER AENEX AEVXI AFKRA AFKWA AFRHN AFTJW AFXIZ AGHFR AHMBA AHPSJ AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PQQKQ PROAC PSQYO R2- RIG ROL RPZ SDF SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ZA5 AAMRU AAXKI AFCTW AKRWK ALIPV NPM AAYXX CITATION 0TZ 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c445t-f5bb69304f64951daae5e632284a6e4334bd7e15cd6e5b4bf3516873c9f6c0d53 |
IEDL.DBID | BENPR |
ISSN | 1470-2045 |
IngestDate | Fri Aug 16 23:31:01 EDT 2024 Thu Oct 10 16:08:55 EDT 2024 Thu Sep 26 19:31:11 EDT 2024 Wed Oct 16 00:49:26 EDT 2024 Fri Feb 23 02:18:58 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | Copyright © 2018 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c445t-f5bb69304f64951daae5e632284a6e4334bd7e15cd6e5b4bf3516873c9f6c0d53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
PMID | 30219628 |
PQID | 2115206869 |
PQPubID | 46089 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2108251541 proquest_journals_2115206869 crossref_primary_10_1016_S1470_2045_18_30497_2 pubmed_primary_30219628 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30497_2 |
PublicationCentury | 2000 |
PublicationDate | October 2018 2018-10-00 20181001 |
PublicationDateYYYYMMDD | 2018-10-01 |
PublicationDate_xml | – month: 10 year: 2018 text: October 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | The lancet oncology |
PublicationTitleAlternate | Lancet Oncol |
PublicationYear | 2018 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Long, Stroyakovsky, Gogas (bib16) 2014; 32 Zimmer, Hillen, Livingstone (bib3) 2012; 30 Robert, Karaszewska, Schachter (bib12) 2015; 372 Koelblinger, Thuerigen, Dummer (bib27) 2018; 30 Dummer, Rinderknecht, Goldinger (bib6) 2012; 366 Delord, Robert, Nyakas (bib22) 2017; 23 Urner-Bloch, Urner, Jaberg-Bentele, Frauchiger, Dummer, Goldinger (bib29) 2016; 65 Flaherty, Infante, Daud (bib8) 2012; 367 Long, Flaherty, Stroyakovskiy (bib20) 2017; 28 Eisenhauer, Therasse, Bogaerts (bib24) 2009; 45 Infante, Falchook, Lawrence (bib9) 2011; 29 Larkin, Del Vecchio, Ascierto (bib15) 2014; 15 Robert, Karaszewska, Schachter (bib28) 2015; 51 Flaherty, Puzanov, Kim (bib4) 2010; 363 (bib13) 2017 (bib25) 2010 Robert, Karaszewska, Schachter (bib18) 2016; 27 Bollag, Hirth, Tsai (bib5) 2010; 467 (bib19) May, 2016 Hwang, Shih, De Cani (bib26) 1990; 9 Long, Stroyakovskiy, Gogas (bib17) 2015; 386 Larkin, Ascierto, Dreno (bib10) 2014; 371 Dummer, Ascierto, Gogas (bib23) 2018; 19 Rinderknecht, Goldinger, Rozati (bib7) 2013; 8 Long, Stroyakovskiy, Gogas (bib11) 2014; 371 Long, Hauschild, Santinami (bib30) 2017; 377 Ascierto, McArthur, Dreno (bib14) 2016; 17 Sullivan, Weber, Patel (bib21) 2015; 33 Davies, Bignell, Cox (bib2) 2002; 417 Krauthammer, Kong, Bacchiocchi (bib1) 2015; 47 30303122 - Lancet Oncol. 2018 Oct;19(10):e509 30219625 - Lancet Oncol. 2018 Oct;19(10):1263-1264 Krauthammer (10.1016/S1470-2045(18)30497-2_bib1) 2015; 47 Infante (10.1016/S1470-2045(18)30497-2_bib9) 2011; 29 Long (10.1016/S1470-2045(18)30497-2_bib17) 2015; 386 (10.1016/S1470-2045(18)30497-2_bib13) 2017 Flaherty (10.1016/S1470-2045(18)30497-2_bib4) 2010; 363 Koelblinger (10.1016/S1470-2045(18)30497-2_bib27) 2018; 30 Flaherty (10.1016/S1470-2045(18)30497-2_bib8) 2012; 367 Larkin (10.1016/S1470-2045(18)30497-2_bib10) 2014; 371 Davies (10.1016/S1470-2045(18)30497-2_bib2) 2002; 417 Hwang (10.1016/S1470-2045(18)30497-2_bib26) 1990; 9 Long (10.1016/S1470-2045(18)30497-2_bib11) 2014; 371 Zimmer (10.1016/S1470-2045(18)30497-2_bib3) 2012; 30 Sullivan (10.1016/S1470-2045(18)30497-2_bib21) 2015; 33 Larkin (10.1016/S1470-2045(18)30497-2_bib15) 2014; 15 Robert (10.1016/S1470-2045(18)30497-2_bib28) 2015; 51 Ascierto (10.1016/S1470-2045(18)30497-2_bib14) 2016; 17 Long (10.1016/S1470-2045(18)30497-2_bib16) 2014; 32 Long (10.1016/S1470-2045(18)30497-2_bib20) 2017; 28 Long (10.1016/S1470-2045(18)30497-2_bib30) 2017; 377 Rinderknecht (10.1016/S1470-2045(18)30497-2_bib7) 2013; 8 Robert (10.1016/S1470-2045(18)30497-2_bib18) 2016; 27 Delord (10.1016/S1470-2045(18)30497-2_bib22) 2017; 23 Dummer (10.1016/S1470-2045(18)30497-2_bib6) 2012; 366 Dummer (10.1016/S1470-2045(18)30497-2_bib23) 2018; 19 Bollag (10.1016/S1470-2045(18)30497-2_bib5) 2010; 467 Eisenhauer (10.1016/S1470-2045(18)30497-2_bib24) 2009; 45 Urner-Bloch (10.1016/S1470-2045(18)30497-2_bib29) 2016; 65 Robert (10.1016/S1470-2045(18)30497-2_bib12) 2015; 372 |
References_xml | – year: 2010 ident: bib25 article-title: Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Cancer therapy evaluation program – volume: 65 start-page: 130 year: 2016 end-page: 138 ident: bib29 article-title: MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects publication-title: Eur J Cancer contributor: fullname: Goldinger – volume: 17 start-page: 1248 year: 2016 end-page: 1260 ident: bib14 article-title: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol contributor: fullname: Dreno – volume: 23 start-page: 5339 year: 2017 end-page: 5348 ident: bib22 article-title: Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma publication-title: Clin Cancer Res contributor: fullname: Nyakas – volume: 372 start-page: 30 year: 2015 end-page: 39 ident: bib12 article-title: Improved overall survival in melanoma with combined dabrafenib and trametinib publication-title: N Engl J Med contributor: fullname: Schachter – volume: 30 start-page: 125 year: 2018 end-page: 133 ident: bib27 article-title: Development of encorafenib for BRAF-mutated advanced melanoma publication-title: Curr Opin Oncol contributor: fullname: Dummer – volume: 363 start-page: 809 year: 2010 end-page: 819 ident: bib4 article-title: Inhibition of mutated, activated BRAF in metastatic melanoma publication-title: N Engl J Med contributor: fullname: Kim – volume: 417 start-page: 949 year: 2002 end-page: 954 ident: bib2 article-title: Mutations of the BRAF gene in human cancer publication-title: Nature contributor: fullname: Cox – volume: 366 start-page: 480 year: 2012 end-page: 481 ident: bib6 article-title: Ultraviolet A and photosensitivity during vemurafenib therapy publication-title: N Engl J Med contributor: fullname: Goldinger – volume: 371 start-page: 1877 year: 2014 end-page: 1888 ident: bib11 article-title: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma publication-title: N Engl J Med contributor: fullname: Gogas – volume: 27 year: 2016 ident: bib18 article-title: Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma publication-title: Ann Oncol contributor: fullname: Schachter – volume: 28 start-page: 1631 year: 2017 end-page: 1639 ident: bib20 article-title: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study publication-title: Ann Oncol contributor: fullname: Stroyakovskiy – volume: 9 start-page: 1439 year: 1990 end-page: 1445 ident: bib26 article-title: Group sequential designs using a family of type I error probability spending functions publication-title: Stat Med contributor: fullname: De Cani – year: 2017 ident: bib13 article-title: Clinical practice guidelines in oncology, melanoma version 1.2018 – year: May, 2016 ident: bib19 article-title: Cotellic (cobimetinib). Full prescribing information – volume: 371 start-page: 1867 year: 2014 end-page: 1876 ident: bib10 article-title: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma publication-title: N Engl J Med contributor: fullname: Dreno – volume: 51 start-page: S663 year: 2015 end-page: S664 ident: bib28 article-title: Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma publication-title: Eur J Cancer contributor: fullname: Schachter – volume: 30 start-page: 2375 year: 2012 end-page: 2383 ident: bib3 article-title: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition publication-title: J Clin Oncol contributor: fullname: Livingstone – volume: 19 start-page: 603 year: 2018 end-page: 615 ident: bib23 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with publication-title: Lancet Oncol contributor: fullname: Gogas – volume: 367 start-page: 1694 year: 2012 end-page: 1703 ident: bib8 article-title: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations publication-title: N Engl J Med contributor: fullname: Daud – volume: 33 start-page: 9007 year: 2015 ident: bib21 article-title: A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment publication-title: J Clin Oncol contributor: fullname: Patel – volume: 32 start-page: 9011 year: 2014 ident: bib16 article-title: COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF publication-title: J Clin Oncol contributor: fullname: Gogas – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib24 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer contributor: fullname: Bogaerts – volume: 47 start-page: 996 year: 2015 end-page: 1002 ident: bib1 article-title: Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas publication-title: Nat Genet contributor: fullname: Bacchiocchi – volume: 29 start-page: CRA8503 year: 2011 ident: bib9 article-title: Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) publication-title: J Clin Oncol contributor: fullname: Lawrence – volume: 8 start-page: e58721 year: 2013 ident: bib7 article-title: RASopathic skin eruptions during vemurafenib therapy publication-title: PLoS One contributor: fullname: Rozati – volume: 15 start-page: 436 year: 2014 end-page: 444 ident: bib15 article-title: Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study publication-title: Lancet Oncol contributor: fullname: Ascierto – volume: 467 start-page: 596 year: 2010 end-page: 599 ident: bib5 article-title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma publication-title: Nature contributor: fullname: Tsai – volume: 377 start-page: 1813 year: 2017 end-page: 1823 ident: bib30 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med contributor: fullname: Santinami – volume: 386 start-page: 444 year: 2015 end-page: 451 ident: bib17 article-title: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial publication-title: Lancet contributor: fullname: Gogas – volume: 367 start-page: 1694 year: 2012 ident: 10.1016/S1470-2045(18)30497-2_bib8 article-title: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations publication-title: N Engl J Med doi: 10.1056/NEJMoa1210093 contributor: fullname: Flaherty – volume: 28 start-page: 1631 year: 2017 ident: 10.1016/S1470-2045(18)30497-2_bib20 article-title: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study publication-title: Ann Oncol doi: 10.1093/annonc/mdx176 contributor: fullname: Long – volume: 23 start-page: 5339 year: 2017 ident: 10.1016/S1470-2045(18)30497-2_bib22 article-title: Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2923 contributor: fullname: Delord – volume: 45 start-page: 228 year: 2009 ident: 10.1016/S1470-2045(18)30497-2_bib24 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 contributor: fullname: Eisenhauer – volume: 47 start-page: 996 year: 2015 ident: 10.1016/S1470-2045(18)30497-2_bib1 article-title: Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas publication-title: Nat Genet doi: 10.1038/ng.3361 contributor: fullname: Krauthammer – volume: 363 start-page: 809 year: 2010 ident: 10.1016/S1470-2045(18)30497-2_bib4 article-title: Inhibition of mutated, activated BRAF in metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1002011 contributor: fullname: Flaherty – volume: 371 start-page: 1877 year: 2014 ident: 10.1016/S1470-2045(18)30497-2_bib11 article-title: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1406037 contributor: fullname: Long – volume: 377 start-page: 1813 year: 2017 ident: 10.1016/S1470-2045(18)30497-2_bib30 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1708539 contributor: fullname: Long – volume: 32 start-page: 9011 year: 2014 ident: 10.1016/S1470-2045(18)30497-2_bib16 publication-title: J Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.9011 contributor: fullname: Long – volume: 29 start-page: CRA8503 year: 2011 ident: 10.1016/S1470-2045(18)30497-2_bib9 article-title: Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.18_suppl.cra8503 contributor: fullname: Infante – volume: 467 start-page: 596 year: 2010 ident: 10.1016/S1470-2045(18)30497-2_bib5 article-title: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma publication-title: Nature doi: 10.1038/nature09454 contributor: fullname: Bollag – volume: 9 start-page: 1439 year: 1990 ident: 10.1016/S1470-2045(18)30497-2_bib26 article-title: Group sequential designs using a family of type I error probability spending functions publication-title: Stat Med doi: 10.1002/sim.4780091207 contributor: fullname: Hwang – year: 2017 ident: 10.1016/S1470-2045(18)30497-2_bib13 – volume: 33 start-page: 9007 year: 2015 ident: 10.1016/S1470-2045(18)30497-2_bib21 article-title: A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.9007 contributor: fullname: Sullivan – volume: 51 start-page: S663 year: 2015 ident: 10.1016/S1470-2045(18)30497-2_bib28 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(16)31820-2 contributor: fullname: Robert – volume: 386 start-page: 444 year: 2015 ident: 10.1016/S1470-2045(18)30497-2_bib17 article-title: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60898-4 contributor: fullname: Long – volume: 30 start-page: 125 year: 2018 ident: 10.1016/S1470-2045(18)30497-2_bib27 article-title: Development of encorafenib for BRAF-mutated advanced melanoma publication-title: Curr Opin Oncol doi: 10.1097/CCO.0000000000000426 contributor: fullname: Koelblinger – volume: 19 start-page: 603 year: 2018 ident: 10.1016/S1470-2045(18)30497-2_bib23 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30142-6 contributor: fullname: Dummer – volume: 372 start-page: 30 year: 2015 ident: 10.1016/S1470-2045(18)30497-2_bib12 article-title: Improved overall survival in melanoma with combined dabrafenib and trametinib publication-title: N Engl J Med doi: 10.1056/NEJMoa1412690 contributor: fullname: Robert – volume: 30 start-page: 2375 year: 2012 ident: 10.1016/S1470-2045(18)30497-2_bib3 article-title: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition publication-title: J Clin Oncol doi: 10.1200/JCO.2011.41.1660 contributor: fullname: Zimmer – volume: 366 start-page: 480 year: 2012 ident: 10.1016/S1470-2045(18)30497-2_bib6 article-title: Ultraviolet A and photosensitivity during vemurafenib therapy publication-title: N Engl J Med doi: 10.1056/NEJMc1113752 contributor: fullname: Dummer – volume: 371 start-page: 1867 year: 2014 ident: 10.1016/S1470-2045(18)30497-2_bib10 article-title: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1408868 contributor: fullname: Larkin – volume: 65 start-page: 130 year: 2016 ident: 10.1016/S1470-2045(18)30497-2_bib29 article-title: MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.06.018 contributor: fullname: Urner-Bloch – volume: 17 start-page: 1248 year: 2016 ident: 10.1016/S1470-2045(18)30497-2_bib14 article-title: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30122-X contributor: fullname: Ascierto – volume: 27 year: 2016 ident: 10.1016/S1470-2045(18)30497-2_bib18 article-title: Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma publication-title: Ann Oncol doi: 10.1093/annonc/mdw435.37 contributor: fullname: Robert – volume: 15 start-page: 436 year: 2014 ident: 10.1016/S1470-2045(18)30497-2_bib15 article-title: Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70051-8 contributor: fullname: Larkin – volume: 417 start-page: 949 year: 2002 ident: 10.1016/S1470-2045(18)30497-2_bib2 article-title: Mutations of the BRAF gene in human cancer publication-title: Nature doi: 10.1038/nature00766 contributor: fullname: Davies – volume: 8 start-page: e58721 year: 2013 ident: 10.1016/S1470-2045(18)30497-2_bib7 article-title: RASopathic skin eruptions during vemurafenib therapy publication-title: PLoS One doi: 10.1371/journal.pone.0058721 contributor: fullname: Rinderknecht |
SSID | ssj0017105 |
Score | 2.7126558 |
Snippet | Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in... Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF -mutant melanoma in the... Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with... BACKGROUNDEncorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1315 |
SubjectTerms | Arthralgia Biotechnology Cancer Clinical trials Creatine Creatine kinase Immunotherapy Melanoma Metastases Metastasis Mutation Myalgia Pain Patients Pharmacology Pruritus Skin cancer Survival |
Title | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial |
URI | https://dx.doi.org/10.1016/S1470-2045(18)30497-2 https://www.ncbi.nlm.nih.gov/pubmed/30219628 https://www.proquest.com/docview/2115206869 https://search.proquest.com/docview/2108251541 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1La9wwEBZNAqWXkj6zTRpU6CGBVWPZkmz3UrJLllC6SUm6sDchWzJdWNvbeJ3_13_WGb9CD2kvPsiSEZ7RzDcPzRDyMQSd5mIpWJbGIROZhCMFdgMDbG-VyOLE53g5eX6lLhfi61IuO4db1aVV9jKxEdS2TNFHfgaGivTxPkP8ZfOLYdcojK52LTR2yJ7PBYZp9yYXV99vhjhC2CYxchF6DAuvP9zhObsdBk94dIrRJtjhY9rpMfTZaKHZPnnewUd63tL7BXniipfk6bwLkL8iv6_v0cm0plUNMgC4iK4K2tVOrSg6Xenk5nxGWV5j-2Cau7UpytxQEHxuhc4F2lS2NJkrVgndrOuKgu28yvFmNAxgEgcM3bu87ueUd38tOZlef1vMJ4vb08_U0CZfsUkAdWOKnboYcJ1bjymoSFsCjzk7ppufoEppQJsOIq_JYnbxY3rJui4NLBVCblkmkwT7KYpMgbHFrTFOOgVyIhJGOREEIrGh4zK1yslEJFkguYrCII0zlXpWBm_IblEW7oDQOJapp9JYRp4VPnCP40aliYytCZX1_BH51FNHb9piHHrIUkNyaiSn5pFuyKlhQdTTUHeIokUKGhTG_5Ye9TTX3bGu9AMTjsiH4TX8LIyymMKVNc5BqxuQKR-Rty2vDJsNAFHFyo_e_fvjh-QZ4LK27C4_Irvbu9q9B-yzTY7JTrgM4RlN-XHH7H8A-t4B8g |
link.rule.ids | 315,786,790,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,43343,43612,43838,74100,74369,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSMAF8WZLASNxaKV1Gye2E3NB7YrVArutRLtSb1YSO2KlTbJtNv1__DNm8qo4FK5OHFmZ8cw3b0I-haDTnJaCZakOmcgkXCmwGxhge6tEphOfY3Hy4lTNluL7pbzsHG5Vl1bZy8RGUNsyRR_5ERgq0sd6Bv1lc8VwahRGV7sRGvfJAxGArsZK8cmQ4sHDNoWRi9Bj2Hb9toLn6HxY3OfRAcaa4Hx36aa7sGejg6ZPyZMOPNLjltrPyD1XPCcPF114_AX5fXaDLqY1rWqQAMBDdFXQrnNqRdHlSk9-Hk8py2scHkxzt46LMo8piD23QtcCbfpaxpkrVgndrOuKguW8yrEuGhYwhQOWblxe9--U139t2Z-czZeLk-X5wWca0yZbsUn_dGOKc7oY8JxbjykoSFsChzk7pptfoEhpQJv5IS_Jcvr1YjJj3YwGlgohtyyTSYLTFEWmwNTiNo6ddAqkRCRi5UQQiMSGjsvUKicTkWSB5CoKg1RnKvWsDF6RnaIs3BtCtZapp1ItI88KH3jH8VilidQ2DpX1_BE57KljNm0rDjPkqCE5DZLT8Mg05DSwIeppaDo80eIEA-rif1v3epqb7lJX5pYFR-Tj8Bh-FsZY4sKVNb6DNjfgUj4ir1teGQ4bAJ7Syo92__3xD-TR7GIxN_Nvpz_ekseA0NoGvHyP7Gyva_cOUNA2ed-w-h91yAGQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdgSBMviG8KA4zEwybVNE5sJ-EFbYNqwLohRqW-WU7siEpNUpZm_x__GXeJ04mHwasTR1bufPe7b0LexqDTXCoFK_I0ZqKQcKXAbmCA7a0SRZqFHIuTZ2fqZC6-LOTC5z81Pq1ykImdoLZ1jj7yCRgqMsR6hnRS-LSIbx-nH9a_GE6QwkirH6dxm9wBLRngGId4sTW-eNynM3IRBwxbsF9X80wutov7PDnAuBOc9SY9dRMO7fTR9D6554EkPewp_4DcctVDsjvzofJH5Pf5FbqbVrRpQRoAP9FlRX0X1Yai-5UefT-cUla2OEiYlm5lqro0FESgW6KbgXY9Lk3hqmVG16u2oWBFL0uskYYFTOeApStXtsM79eVfW_aPz0_ns6P5xcF7amiXudilgroxxZldDPjPrcYUlKWtgducHdP1T1CqNKLdLJHHZD799OP4hPl5DSwXQm5YIbMMJyuKQoHZxa0xTjoFEiMRRjkRRSKzseMyt8rJTGRFJLlK4ihPC5UHVkZPyE5VV-4ZoWkq80DlqUwCK0LgI8eNyjOZWhMrG4Qj8m6gjl73bTn0Nl8NyamRnJonuiOnhg3JQEPtsUWPGTSojv9t3Rtorv0Fb_Q1O47Im-1j-FkYbzGVq1t8B-1vwKh8RJ72vLI9bATYKlVh8vzfH39NdoHL9enns68vyF0Aa30vXr5HdjaXrXsJgGiTveo4_Q_qhAXx |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overall+survival+in+patients+with+BRAF-mutant+melanoma+receiving+encorafenib+plus+binimetinib+versus+vemurafenib+or+encorafenib+%28COLUMBUS%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Dummer%2C+Reinhard&rft.au=Ascierto%2C+Paolo+A&rft.au=Gogas%2C+Helen+J&rft.au=Arance%2C+Ana&rft.date=2018-10-01&rft.eissn=1474-5488&rft.volume=19&rft.issue=10&rft.spage=1315&rft.epage=1327&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930497-2&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |